Pfizer Inc (PFE)

PFE on New York Consolidated

34.49USD
2 Jun 2015
Change (% chg)

$-0.07 (-0.20%)
Prev Close
$34.56
Open
$34.64
Day's High
$34.66
Day's Low
$34.35
Volume
18,666,242
Avg. Vol
26,187,578
52-wk High
$35.53
52-wk Low
$27.51

PFE

Chart for PFE

About

Pfizer Inc. is a bio pharmaceutical company. The company applies science and resources to discover, develop and manufacture healthcare products. The Company provides medicines, vaccines and consumer healthcare products. The Company operates its business through three operating segments, which include Global Innovative Pharmaceut... (more)

Overall

Beta: 0.73
Market Cap(Mil.): $212,809.09
Shares Outstanding(Mil.): 6,157.67
Dividend: 0.28
Yield (%): 3.24

Financials

  PFE Industry Sector
P/E (TTM): 23.90 36.48 38.67
EPS (TTM): 1.45 -- --
ROI: 6.44 16.42 15.73
ROE: 12.69 17.24 16.79
Search Stocks

Merck KGaA sees immunotherapy drug holding its own in cancer race

FRANKFURT - The head of Merck KGaA's healthcare division said she expected its cancer drug avelumab, jointly developed with Pfizer, to be among the first two or three to market in a field of immunotherapy pharmaceuticals that harness the power of the immune system in a range of cancer types.

01 Jun 2015

Merck KGaA sees immunotherapy drug holding its own in cancer race

FRANKFURT, June 1 - The head of Merck KGaA's healthcare division said she expected its cancer drug avelumab, jointly developed with Pfizer, to be among the first two or three to market in a field of immunotherapy pharmaceuticals that harness the power of the immune system in a range of cancer types.

01 Jun 2015

Pfizer's Ibrance drug slows progression of breast cancer

CHICAGO - A Phase III trial of Pfizer Inc's Ibrance showed that, in combination with hormone therapy, the drug more than doubled the duration of disease control for women with the most common type of breast cancer.

30 May 2015

UPDATE 1-Pfizer's Ibrance drug slows progression of breast cancer

CHICAGO May 30 - A Phase III trial of Pfizer Inc's Ibrance showed that, in combination with hormone therapy, the drug more than doubled the duration of disease control for women with the most common type of breast cancer.

30 May 2015

Pfizer's Ibrance drug slows progression of breast cancer

CHICAGO May 30 - A Phase III trial of Pfizer Inc's drug Ibrance showed that, in combination with hormone therapy, the drug more than doubled the duration of disease control for women with the most common type of breast cancer.

30 May 2015

French biotech firm Cellectis jumps on takeover hopes

- Shares in French cancer drugmaker Cellectis hit an all-time high on Friday on hopes it would be the latest in a string of bid targets in the healthcare sector, after reported interest from companies including Pfizer .

29 May 2015

UPDATE 2-French biotech firm Cellectis jumps on takeover hopes

May 29 - Shares in French cancer drugmaker Cellectis hit an all-time high on Friday on hopes it would be the latest in a string of bid targets in the healthcare sector, after reported interest from companies including Pfizer .

29 May 2015

French drugmaker Cellectis in sale talks: FT

- French cancer drugmaker Cellectis is in potential sale talks with a few suitors, including U.S. based Pfizer Inc , the Financial Times reported citing people familiar with the matter.

28 May 2015

French drugmaker Cellectis in sale talks -FT

May 28 - French cancer drugmaker Cellectis is in potential sale talks with a few suitors, including U.S. based Pfizer Inc, the Financial Times reported citing people familiar with the matter.

28 May 2015

UPDATE 1-FDA approves Pfizer drug to treat very rare lung disease

WASHINGTON, May 28 - The U.S. Food and Drug Administration on Thursday approved the first drug to treat a rare, progressive lung disease that mainly affects women of childbearing age.

28 May 2015

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $99.98 -0.06
Novartis AG (NOVN.VX) CHF96.30 -1.10
Merck & Co., Inc. (MRK.N) $60.24 -0.51
Roche Holding Ltd. (ROG.VX) CHF275.30 -4.40
Abbott Laboratories (ABT.N) $48.94 0.00
Bayer AG (BAYGn.DE) €128.75 -1.55
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €89.64 -0.42
AstraZeneca plc (AZN.L) 4,357.00p -9.50
GlaxoSmithKline plc (GSK.L) 1,441.00p -15.00

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: GlobalData
$125.00
Provider: ValuEngine, Inc.
$49.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks